Employers are spending more than ever on employee health and wellbeing. But despite the investment, engagement is low. Outcomes aren’t improving. And costs keep rising. It’s time to rethink wellbeing. Not as a set of perks, but as a scalable strategy for addressing the root causes of chronic disease.
Backed by clinical insight and guided by Personify Health’s Science Advisory Board, this piece explores why reducing systemic chronic inflammation may be the most powerful lever for improving health outcomes, boosting engagement, and controlling cost—through a more biological, behavior-based approach to wellbeing.
$4.9 trillion.
That’s how much we spend on healthcare in the U.S.
90% of that is spent on individuals with chronic conditions. And 70% of those chronic conditions are driven by one thing no one’s talking about:
Systemic chronic inflammation: A persistent, body-wide immune response that stays slightly activated even without infection or injury, gradually damaging tissues, disrupting function, and increasing chronic disease risk.
It’s also the hidden force shaping medication trends, employee wellbeing, and the very structure of healthcare spending.
But we didn’t set out looking for inflammation.
Over the past two years, myself and Personify Health’s Science Advisory Board have been digging into the underlying drivers of rising healthcare costs and complexity.
We were searching for the patterns behind the problem. And what we found surprised us.
Systemic chronic inflammation was at the center of all of it.
That’s the real root cause of America’s trillion-dollar health crisis.
The starting point: GLP-1s
Funny enough, our path to that insight didn’t begin with inflammation.
It began with GLP-1s, the weight loss and diabetes drugs that, almost overnight, became the center of every strategy conversation.
Since they came onto the scene, each one of us on the Science Advisory Board has been in hundreds of conversations about these medications with customers, prospects, and clinical colleagues. It wasn’t just a hot topic. It was the topic.
Every C-suite was talking about them. Costs were skyrocketing. Employers were seeing 50% year-over-year increases in spend. Everyone wanted to know what to do about GLP-1s; how to manage them, how to afford them, and how to decide who needed them.
Initially, we treated it as a standalone issue. A utilization spike to be explained.
But the sheer volume and urgency of the conversation told us there was more going on. Something deeper.
That’s when we started asking a different question: Why now?
Why are these drugs exploding in popularity today and not five or ten years ago? What’s changed? What’s the deeper need they’re tapping into?
Why GLP-1s took off
We started looking for patterns and trends, anything that might help explain the timing, intensity, and demand of this drug.
And then we saw this chart showing GLP-1 prescription rates alongside Google search interest and it all made sense.
On one side, you have the number of people being prescribed drugs like Ozempic, Wegovy, and Mounjaro. On the other, how often those same terms were being searched online.
The two lines moved almost in lockstep. As people’s curiosity in the drug climbed, so did the frequency of prescribing it.
What it made clear, beyond the numbers, was that this wasn’t just a clinical response. It was a cultural one. People weren’t passively receiving care. They were actively looking for it. They were searching, asking, sharing, and demanding.
And that demand wasn’t just about weight loss or blood sugar control. It was bigger and more urgent.
GLP-1s were filling a void — but not the one we thought.
So we started asking a different question:
What exactly is this medication solving for?
Not just clinically, but emotionally. Biologically. Systemically.
What’s the pain people are trying to escape?
What demand for GLP-1s tells us about the system people are trying to escape
The answer can be found by looking at how we live and our modern Western lifestyles.
We eat food packed with sugar and chemicals, we sit more than we move, we sleep less, stress more, and live alone more than ever before.
This lifestyle doesn’t just increase our risk of disease. It creates the conditions for disease by driving chronic inflammation in the body.
And inflammation is no small thing. It can be linked to 70% of all chronic conditions.
That’s why GLP-1s have become such a phenomenon. On the surface, they’re marketed as weight loss and diabetes drugs. But what’s striking is their impact across the entire body.
These drugs are helping people feel better not just because they’re losing weight, but because they’re dialing down inflammation throughout the body. That starts to explain why demand has exploded. People aren’t just seeking weight loss. They’re seeking relief.
And when you zoom out, you can see why:
In the past 40 years, obesity rates in the U.S. haven’t just risen — they’ve doubled. Twice.
But here’s the key point: Obesity isn’t the root problem. It’s a symptom. A symptom of a system and a lifestyle that overwhelms the body’s ability to regulate itself.
So yes, GLP-1s might be helping people manage their weight. But that’s a bit like polishing a car that can’t run. GLP-1s are addressing the surface, not the source. And the real source? It’s systemic chronic inflammation, which is linked to 70% of all chronic conditions, which are largely driven by how we live. That’s why I always say: 70% to 80% of health is lifestyle modifiable.
If we don’t treat this inflammation, the underlying condition that’s causing the costliest diseases in the first place, we’ll keep mistaking symptoms for causes and stay trapped in a system that treats illness instead of creating health.
And once we started seeing inflammation in the GLP-1 story, we started seeing it everywhere.
The red thread that kept showing up
Around the same time, we were conducting a wide range of clinical deep dives into topics like menopause, metabolic health, mental health, sleep, and behavioral outcomes.
We weren’t looking for a unifying explanation. Each topic had its own complexity, data, and causes. But systemic chronic inflammation kept surfacing across every area we explored.
We saw it influencing metabolism. Sleep. Cognition. Mood. Disease progression. It didn’t matter which area we were exploring, the same mechanism kept appearing in the background.
That’s when the larger picture started to come into focus.
This wasn’t just about weight gain or prescription trends. It wasn’t even about GLP-1s.
Systemic chronic inflammation wasn’t just part of the story. It was the story. We just hadn’t been looking at it that way.
Chronic inflammation rewrites the math on healthcare spend
Once you understand how many of those chronic conditions are either caused or worsened by low-grade inflammation, you realize that we’re not just spending trillions on long-term disease. We’re spending it on the downstream effects of something we rarely name, track or treat directly.
Based on clinical literature, at least 70% of chronic conditions are linked to systemic chronic inflammation. And yet, it’s almost completely absent from how we design, deliver, and pay for care.
If we want to lower the cost of care, improve population health, or build a more resilient workforce, we can’t just manage downstream disease. We have to start addressing what’s upstream.
And yet, inflammation is almost entirely absent from the conversation.
It’s not something we talk about in vendor selection.
It’s not something we screen for in wellbeing programs.
It’s not part of most benefits strategies at all.
Somehow, we’ve built an entire system around treating the effects of inflammation without ever naming it as a cause.
And nowhere is that more obvious than in how we think about wellbeing.
Rethinking wellbeing
For years, we’ve treated “wellbeing” as a category, a collection of programs and perks designed to support employees beyond traditional healthcare.
But somewhere along the way, the concept got diluted.
It became a checklist: sleep tools, fitness discounts, mental health apps, nutrition coaching. A series of disconnected features, none of which added up to a coherent strategy.
But the science is clear: chronic, low-grade inflammation affects everything from metabolic function to mood regulation to cognitive performance. It’s what links stress to disease, poor sleep to burnout, loneliness to immune dysfunction.
So, when we talk about “wellbeing,” we’re not talking about something soft.
We’re talking about the biological infrastructure that enables people to thrive (or fail) inside the systems we’ve built.
That’s the shift we need. Not more features. Not more point solutions.
A redefinition of wellbeing as the work of reducing systemic chronic inflammation, at scale, and by design.
That’s where the opportunity is. And that’s where we need to go, not just as a company, but as an industry.
We know that 70–80% of health outcomes are lifestyle modifiable. Which means inflammation isn’t just treatable — it’s preventable. But only if we’re willing to address the root behaviors that drive it.
That’s the hard part.
Because changing behavior isn’t about willpower. It’s about environment, design, motivation, and science — the kind of science that underpins everything we’ve built at Personify Health.
In our next post, we’ll explore what it really takes to reduce systemic chronic inflammation in the real world — and why behavior change is the true unlock to better health, lower costs, and a more resilient workforce.
About the author
Dr. Jeff is passionate about finding ways to combine technology and human expertise to support people going through difficult and highly personal health journeys. This commitment is fueled by his personal experiences and frustrations with the healthcare system, which drove him to innovate and bring change to the industry. He currently serves as Personify Health’s chief medical officer. At Personify Health, he focuses on ensuring alignment with member and market needs, enhancing the company’s behavior science approach, and exploring additional ways our unique capabilities can further simplify and support the member journey. He is also an entrepreneur with more than 20 years of experience building solutions that deliver personalized support for individuals experiencing complex care journeys.